Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BICRA antisense RNA 1 (BICRA-AS1)
- Target
- BICRA-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01
Overview
BICRA antisense RNA 1 is a long non-coding RNA gene (lncRNA), annotated in multiple genomic databases and classified as a natural antisense transcript (NAT)[3]. Its alternate name is GLTSCR1-AS1[1][3]. Like other antisense lncRNAs, it is thought to modulate the expression of nearby or overlapping protein-coding genes—here, BICRA—by mechanisms that may include chromatin remodeling, transcriptional interference, and regulation of RNA stability[2][4]. While antisense lncRNAs as a class play roles in development, cell cycle, and various diseases such as cancer, no direct functional, disease, or drug-related data exists for BICRA-AS1 itself in the current literature. The molecule is not considered a classic therapeutic target, such as a receptor or enzyme, and there are no known interacting drugs, disease associations, or biomarker applications at this time[1][3][4].
- Other names
- GLTSCR1-AS1
02
Biological functions
Regulation of gene expression (at the transcriptional, epigenetic, and post-transcriptional levels)Modulation of RNA stabilityPotential involvement in chromatin modification and transcriptional interference
03
Disease associations
Other
Beyond the preview
Go deeper on BICRA antisense RNA 1 (BICRA-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BICRA antisense RNA 1 (BICRA-AS1).